Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1045843 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL29623519 | 1.00 | CETP (1.00) | CETP | |
| SCHEMBL6136769 | 0.93 | CETP (1.00) | CETP | |
| SCHEMBL6306804 | 0.90 | CETP (0.82) | CETP | |
| SCHEMBL6307876 | 0.90 | CETP (0.81) | CETP | |
| SCHEMBL5180245 | 0.90 | CETP (0.81) | CETP | |
| SCHEMBL5180532 | 0.90 | CETP (0.81) | CETP | |
| SCHEMBL13385240 | 0.89 | CETP (0.83) | CETP | |
| SCHEMBL993531 | 0.89 | CETP (1.00) | CETP | |
| SCHEMBL993671 | 0.89 | CETP (1.00) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 571 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY (SA) | 2018-02-22 | — | — | US | claimed |
| US-9265731-B2 | Drying of drug-containing particles | BEND RESEARCH, INC. (US) | 2016-02-23 | — | — | US | claimed |
| EP-1855652-B1 | DRYING OF DRUG-CONTAINING PARTICLES | BEND RES INC (US) | 2015-12-02 | — | — | EP | claimed |
| US-8828438-B2 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase | BEND RESEARCH, INC. (US) | 2014-09-09 | — | — | US | claimed |
| US-8703204-B2 | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-8703199-B2 | Pharmaceutical compositions of adsorbates of amorphous drug | BEND RESEARCH, INC. (US) | 2014-04-22 | — | — | US | claimed |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | FELSTEAD STEPHEN JOHN | 2010-10-21 | — | — | US | claimed |
| US-20100129447-A1 | NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER | BEND RESEARCH, INC. | 2010-05-27 | — | — | US | claimed |
| US-7700658-B2 | (R)-chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesterol ester transfer protein activity | PFIZER INC. (US) | 2010-04-20 | — | — | US | claimed |
| US-20100062073-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN | BEND RESEARCH, INC. | 2010-03-11 | — | — | US | claimed |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | PFIZER INC | 2004-09-23 | — | — | US | claimed |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | PFIZER INC | 2004-07-08 | — | — | US | claimed |
| WO-2004056395-A1 | COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-COA REDUCTASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2004-07-08 | — | — | WO | claimed |
| US-6723752-B2 | ATHEROSCLEROSIS; CARDIOVASCULAR DISORDERS | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | claimed |
| US-20030186952-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | PFIZER INC. | 2003-10-02 | — | — | US | claimed |
| WO-2003063832-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A SOLID AMORPHOUS DISPERSION OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-08-07 | — | — | WO | claimed |
| US-20030050317-A1 | (R)-chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-03-13 | — | — | US | claimed |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-02-27 | — | — | US | claimed |
| US-20030027826-A1 | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2003-02-06 | — | — | US | claimed |
| US-20020177708-A1 | (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186952-A1 | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors | CETP, HDLBP, NPC1L1 | CETP 1/4885 |
| US-20030027826-A1 | (R)-Chiral halogenated substituted heteroaryl benzyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CETP 1/4885 |
| US-20020177708-A1 | (R)-chiral halogenated substituted N-benzyl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, MTTP | CETP 1/4885 |
| US-20100129447-A1 | NANOPARTICLES COMPRISING A CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITOR AND ANON-IONIZABLE POLYMER | CETP, CHLSN, PCTP | CETP 1/4885 |
| US-20040185102-A1 | Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor | CETP, HMGCR, MTTP | CETP 1/4885 |
| US-20030040545-A1 | (R)-Chiral halogenated substituted fused heterocyclic amino compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PLTP | CETP 1/4885 |
| US-20100062073-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES COMPRISING ENTERIC POLYMERS CASEIN | CSNK1G3, CSNK2A3, CSNK1A1 | CETP 54/4885 |
| US-20100267765-A1 | Pharmaceutical Compositions and Methods for CCR5 Antagonists | CETP, CCR5, MTTP | CETP 1/4885 |
| US-20180049997-A1 | CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) INHIBITION IN THE TREATMENT OF CANCER | CETP, LCAT, MTTP | CETP 1/4885 |
| US-20030050317-A1 | (R)-chiral halogenated substituted n,n-bis-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | CETP 1/4885 |
| US-20040132771-A1 | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors | CETP, HMGCR, CHLSN | CETP 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.